The combination of a minimally invasive endoscopic sleeve gastroplasty (ESG) with the diabetes drug semaglutide can bring additional significant weight loss to patients who are not eligible for invasive weight loss surgery. This is based on research selected for presentation at Digestive Disease Week (DDW) 2021.
“As the global obesity rate continues to rise, so will the number of people seeking bariatric surgery to treat their condition,” said Dr. Anna Carolina Hoff, lead researcher on the study and founder and clinical director of Angioskope Brazil, São José dos Campos. “Surgical interventions are some of the most successful ways to help patients lose weight, but they can lead to complications. Our study shows that patients may not need to undergo invasive surgery to achieve similar results.”
In a double-blind study, researchers randomized 61 patients undergoing ESG into two groups, with a group of 29 patients starting semaglutide – an injectable glucagon-like peptide-1 receptor known to stimulate weight loss received one month after the procedure. Another group of 29 patients received a placebo given with similar pen pens. Three patients were lost to follow-up care. Participants were monitored for body weights and composition every month, and blood tests were performed every three months.
Patients who received semaglutide lost an average of 26.7 percent of their total body weight compared to the control group, who lost an average of 19.6 percent of their total body weight. The semaglutide group lost 86.3 percent of their excess weight – the amount of weight patients had to lose to achieve a normal BMI – compared to 60.4 percent for the control group. The semaglutide group also lost 12.7 percent by weight of their body fat compared to 9 percent for the control group. Eventually glycated hemoglobin (Hb1Ac) levels fell by 0.95 for the semaglutide group and by 0.61 for the controls.
Surgical interventions such as laparoscopic sleeve gastrectomy are associated with increased costs and a higher risk of complications such as gastroesophageal reflux disease or GERD. These surgeries are typically limited to those with a BMI of at least 35 with comorbidities or those with a BMI over 40. ESG can be done at an earlier stage of the disease and at a lower BMI, so more patients can get the treatment they need before their disease progresses. Treating obese patients earlier can help reduce death and comorbidities, as well as lower the costs associated with treating these conditions.
“ESG has been available to patients for years, but has not always been as successful as surgical options in helping patients lose weight,” said Dr. Hope “We now have a minimally invasive procedure that, when combined with semaglutide, can be just as effective and made available to even more people looking to lose a significant amount of weight.”
ESG is performed by inserting a device through the patient’s throat into the stomach, where an endoscopist uses sutures to shrink the stomach. This helps patients lose weight by limiting the amount they can eat. Patients are candidates for ESG if they have a BMI of 30 or greater and diet and exercise have not helped them lose weight, or if they are not candidates for surgery or if they do not want to have surgery.
The researchers warn that the long-term durability of the treatment has yet to be determined.
Weekly semaglutide is the best placebo for major weight loss
Provided by Digestive Disease Week
Quote: Combining a bariatric procedure with a diabetes drug increases weight loss (2021 May 14), accessed May 14, 2021 from https://medicalxpress.com/news/2021-05-pairing-bariatric-procedure-diabetes -drug.html
This document is subject to copyright. Except for fair trade for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.
